{"changeSha256":"632b1a3648840b4988cc4cbb48dc70186de64f9addff8c0d95c87322f81cea09","changedAt":"2026-11-16","changedFields":[{"after":"A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.","before":"The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.","field":"Evidence note"},{"after":"ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d, journal-pmid-42810355, ctg-observation-nct07843498-2026-11-05-9b532d149aaf, ctg-observation-nct07076030-2026-01-28-68a10be352b4","before":"ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d","field":"Cited source records"},{"after":"name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42810355, journal-pmid-42017294, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b","before":"name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/petrelintide/versions/4/","version":4},"id":"profile:petrelintide:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials.","peptideSlugs":["petrelintide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/petrelintide/v3.json","sha256":"6cc9047f6b7368f90fbeef5367f929d23852d95bb29ffe00542db9b600e1522e"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/petrelintide/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"journal-pmid-42810355","name":"The Lancet Diabetes & Endocrinology","sourceClass":"A","title":"Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial (2026) · PMID 42810355","url":"https://doi.org/10.1016/S2213-8587(26)00213-5","verifiedAt":"2026-11-16"},{"id":"ctg-observation-nct07843498-2026-11-05-9b532d149aaf","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07843498 · retained source version 2026-11-05:9b532d149aaffed6b38bd85ef1731c2342003d62a19554586ffc692016cb1e62","url":"https://clinicaltrials.gov/study/NCT07843498","verifiedAt":"2026-11-14"}],"subject":{"slug":"petrelintide","type":"profile"}}
